

Innovations in the pharmacological treatment of pain 2018

Dr Satbir Singh Jassal MBE
General Practitioner
Medical Director
Rainbows Hospice for
Children and Young Adults
Loughborough, Leicestershire, UK



Contents

- Principals
- Distress vs pain
- Specific drugs
- Drug routes
- Evidence base



Principles

- Keep it simple
- Don't try to be too clever



- Innovation doesn't not mean using obscure drugs.
- Learn how to use existing medication correctly



- Children are not small adults
- Neonates are not small children
 - Drug absorption
 - Drug distribution
 - Drug metabolism
 - Drug excretion

APPM formulary has neonatal doses.



Consider distress rather than pain

- Pain Syndrome –
 - Central pain (TCA)
 - Visceral hyperalgesia (gabapentin)
 - Dysautonomia (clonidine)



Consider distress rather than pain

- Dystonia – standard baclofen
 - Trihexyphenidyl (past)
 - Gabapentin (present)
 - Risperidone (future)



Gabapentin vs Pregabalin

- *Gabapentin my first choice*
- Pregabalin (unlicensed in <18yrs)
 - Binding affinity 6 times greater cf gabapentin
 - Oral bioavailability >90%
 - Doesn't bind to plasma proteins
 - Ok in hepatic impairment
 - Caution in renal disease



Clonidine

- Dystonia
- Dysautonomia
- Synergistic analgesia with opioids
- Effects abolished by TCA /antipsychotic
- Patches available



Patch

- Lidocaine
- Fentanyl
- Buprenorphine
- Clonidine



Old drugs to reconsider

- Ketamine
- Methadone.



New routes Transmucosal

Drug absorption generally efficient:

- No stratum corneum (unlike skin)
- Rich blood supply to move drug to circulation
- Avoids first pass metabolism (liver)
- Avoids degradation in the GI tract



Transmucosal

- Drugs can pass through the cells (transcellular) if they are lipophilic
- They can go between cells if they are hydrophilic and small enough
- The pH of the drug and how ionised it is also affect how well it is absorbed
- Buccal enhancers have also been developed by drug companies to increase muco-adhesiveness or speed of absorption



What makes the ideal drug?

Oral transmucosal drug delivery for pediatric use

Jenny K.W. Lam ^{*}, Yingying Xu, Alan Worsley, Ian C.K. Wong

The summary of ideal physicochemical properties of drug candidates for buccal or sublingual formulation development.

Parameters	Ideal properties
High potency	Single dose < 10 mg
High lipophilicity	Log <i>P</i> (octanol/water) > 2.0
Fairly good water solubility	Select drug salts with good solubility if necessary
Acid/base properties	Unionized form at mucosal
Small molecular size	Smaller the better, less than 800 Da

Transmucosal

- Midazolam (seizures, agitation, anxiety)
- Fentanyl (breakthrough pain)
- Diamorphine (breakthrough pain)
- Ketamine (breakthrough neuropathic pain)
- Levomepromazine (nausea / vomiting)
- Buscopan (colicky pain bowel / urinary tract)

Patient and family empowerment.



Evidence

- In the good old days
 - maxi dose of midazolam in syringe driver
- The reality of evidence based medicine
 - Morphine given buccally



Morphine given buccally – the question

- Delphi study (Lynda Brookes) – 50% units used morphine, 50% diamorphine. Very few fentanyl ?why.
- Our review of evidence – 50:50 split as to whether it works.



Morphine given buccally – the answer

Use of buccal morphine in the management of pain in children with life-limiting conditions: Results of a Laboratory study

Renée McCulloch¹³, Mohammed Sattar², Ellen M Henderson³, Majella E Lane⁴, Myra BluebondLangner³⁵

Palliative Medicine, vol. 32, 2: pp. 554-558. , First
Published June 20, 2017.

- **Not absorbed**



Where to get help

- APPM drug formulary
[http://www.appm.org.uk/
10.html](http://www.appm.org.uk/10.html)



Thank you for coming
and listening

